Immunai said the new funding will allow it to expand its genomics capabilities from the observational to the functional, including reprogramming immune cells as well as prioritizing and validating targets . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge